SCHEMBL5887166

SCHEMBL5887166

COC1=CC[CH]C(c2ccccc2Cl)=C1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.34
HTR7 P34969 7/20 0.33
HTR1A P08908 6/20 0.33
HTR2B P41595 6/20 0.33
HTR5A P47898 6/20 0.33
HTR6 P50406 6/20 0.33
HTR1D P28221 5/20 0.33
HTR1B P28222 5/20 0.33
HTR2A P28223 5/20 0.33
HTR2C P28335 4/20 0.33
HTR1E P28566 4/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
HTR3A P46098 1/20 0.33
CASP3 P42574 2/20 0.33
SENP7 Q9BQF6 2/20 0.33
SENP6 Q9GZR1 2/20 0.33
SENP8 Q96LD8 1/20 0.33
HSD11B1 P28845 1/20 0.33
ALDH1A1 P00352 3/20 0.32
NPC1 O15118 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6047599 0.74 IDO1 (0.39) ALDH1A1NPC1LMNAMAPTMEN1
SCHEMBL6047614 0.72 HSD11B1 (0.34) CYP2A6HSD11B1ALDH1A1NPC1RAB9A
SCHEMBL6047640 0.70 MAPT (0.36) ALDH1A1NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL6047643 0.70 P2RX7 (0.37) MEN1KMT2ATSHR
SCHEMBL4806936 0.67 ACHE (0.35) NPC1RAB9AKMT2A
SCHEMBL6047596 0.66 ABL1 (0.45) HTR7HTR1AALDH1A1NPC1RAB9A
SCHEMBL4804654 0.66 ACHE (0.39) HTR2CL3MBTL1ALDH1A1NPC1RAB9A
SCHEMBL4012746 0.63 NOTUM (0.36) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL4742508 0.62
SCHEMBL4015171 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US disclosed
US-20050026903-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-03 US disclosed
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders JONES TODD K (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders CCKAR, CCKBR, NPY1R CYP2A6 561/4885HTR7 76/4885HTR1A 9/4885
US-20050026903-A1 CCK-1 receptor modulators CCKAR, CCKBR, GLP1R CYP2A6 985/4885HTR7 104/4885HTR1A 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.